Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTO: PLX-PAD Cells for Mild to Moderate Knee Osteoarthritis
2023-504212-15-00Phase 2Withdrawn
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing PLX-PAD (EMIPLACEL) with Placebo (2 arms). Primary endpoint: Safety of PLX-PAD cell treatment. Planned start Mar 2024; status: withdrawn.
02
Drugs
PLX-PAD
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-504212-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504212-15-00.